Metastatic breast cancer (MBC) is an advanced stage of breast cancer where the disease has spread beyond the breast to distant organs such as bones, liver, or lungs1. Although considered incurable, treatment advances have extended survival and improved symptom control, with about 31% of patients living five years or more after diagnosis23. Treatment depends on tumor biology, metastatic sites, and patient factors, aiming to control disease progression and maintain quality of life42.
Drug Therapies for Metastatic Breast Cancer
Systemic drug therapies form the cornerstone of metastatic breast cancer treatment. These include hormone therapy, chemotherapy, targeted therapy, immunotherapy, and bone-strengthening drugs. Treatment choice depends on cancer subtype, receptor status, metastatic location, menopausal status, and patient health421.
Hormone Therapy
Hormone therapy targets hormone receptor-positive (HR+) metastatic breast cancers, which express estrogen and/or progesterone receptors and grow in response to these hormones56. Endocrine therapies inhibit estrogen signaling to slow tumor growth and include aromatase inhibitors, selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs)78.
Some HR+ breast cancers develop resistance due to estrogen receptor mutations (ESR1 mutations), which can be detected early by circulating tumor DNA (ctDNA) analysis910. Next-generation SERDs such as camizestrant, vepdegestrant, and imlunestrant have shown improved progression-free survival in patients with ESR1 mutations101112. Combining hormone therapy with agents like CDK4/6 inhibitors and PI3K inhibitors (e.g., inavolisib) can further improve outcomes and delay the need for chemotherapy by about two years1012.
Common hormone therapies include tamoxifen, anastrozole, exemestane, letrozole, and fulvestrant1314. Menopausal status influences the choice of endocrine therapy, with ovarian function suppression added in premenopausal women to improve outcomes712.
Chemotherapy
Chemotherapy uses drugs that kill rapidly dividing cancer cells and is often employed for patients with hormone receptor-negative tumors or when hormone therapy is no longer effective151. It can shrink tumors, improve symptoms, and extend survival but is associated with more side effects than targeted therapies1513.
Chemotherapy regimens are selected based on prior treatments, tumor subtype, and patient health. High-dose chemotherapy followed by stem cell rescue is under investigation to restore bone marrow function after intensive treatment16. Chemotherapy is also combined with targeted agents in HER2-positive disease to enhance efficacy17.
Targeted Therapy
Targeted therapies focus on specific molecular markers in cancer cells, offering more precise treatment with fewer effects on normal cells1513. HER2-targeted therapies have revolutionized treatment for HER2-positive metastatic breast cancer, which accounts for about 20% of cases18517.
Standard first-line treatment for HER2-positive MBC combines chemotherapy with dual monoclonal antibodies trastuzumab and pertuzumab, followed by maintenance therapy with these agents17. Newer agents like trastuzumab deruxtecan (T-DXd) and tucatinib have improved progression-free survival and reduced brain metastases risk1712.
Other targeted therapies include PI3K inhibitors, CDK4/6 inhibitors, and PARP inhibitors for patients with specific mutations such as BRCA101. These agents can be combined with hormone therapy or chemotherapy depending on tumor characteristics.
Immunotherapy
Immunotherapy stimulates the immune system to attack cancer cells and is particularly active against triple-negative breast cancer (TNBC), an aggressive subtype more common in younger patients1920. Immune checkpoint inhibitors (ICIs) are approved in combination with chemotherapy or as single agents for patients with high tumor mutational burden or mismatch repair deficiency201.
Recent trials show that combining sacituzumab govitecan with pembrolizumab improves progression-free survival in PD-L1-positive advanced TNBC compared to chemotherapy plus pembrolizumab1012. Immunotherapy is becoming an important option for selected patients with metastatic breast cancer.
Bone-Strengthening Drugs
Bone metastases are common in metastatic breast cancer and can cause pain, fractures, and other complications4. Bone-strengthening drugs such as bisphosphonates and denosumab help reduce skeletal-related events by inhibiting bone resorption1513.
These agents are used alongside systemic therapies to improve quality of life and reduce complications from bone metastases.
Bone-strengthening drugs play a vital role in managing metastatic breast cancer by preventing fractures and reducing bone pain, thus enhancing patient comfort and mobility1315.
Radiation Therapy for Metastasis
Radiation therapy uses high-energy rays to target and destroy cancer cells in specific body areas21. It is generally not curative for widespread metastatic disease but is used selectively for symptom control2221.
Radiotherapy is indicated for palliation of painful metastases, prevention or treatment of fractures, bleeding, or nerve compression2113. It can be delivered as external beam radiation, which directs rays from outside the body, or brachytherapy, which places radioactive sources near tumors21.
Side effects include acute fatigue, skin reactions, and potential late organ toxicity. Brachytherapy may cause local tissue irritation, pain, or infection21.
Surgical Interventions
Surgery is infrequently used in metastatic breast cancer and is primarily reserved for symptom control21. It aims to excise tumor masses to reduce tumor burden, relieve pain, or manage complications such as fractures or blockages2113.
Complete surgical removal is rarely possible due to the widespread nature of metastatic disease21. Postoperative radiotherapy may be used to control residual disease or symptoms21.
Palliative Care Services
Palliative care focuses on symptom relief and improving quality of life for patients with serious illnesses like metastatic breast cancer21. It is integrated with oncology care to provide comprehensive symptom management, including pain control and emotional support21.
Palliative care teams typically include physicians, nurses, social workers, and chaplains who address physical, emotional, social, and spiritual needs21. Early integration of palliative care improves symptom control and quality of life21.
Early palliative care integration helps manage pain and emotional distress, supporting patients and families throughout metastatic breast cancer treatment21.
Complementary and Alternative Therapies
Complementary therapies may be used alongside conventional treatments to support symptom management and reduce side effects such as anxiety and fatigue21. These approaches include mind-body techniques, relaxation therapies, and nutritional support21.
While not curative, complementary therapies can improve overall well-being and quality of life when used appropriately with standard care21.
Clinical Trial Participation
Clinical trials are essential for investigating new therapies and combinations to improve metastatic breast cancer treatment23. They contribute to understanding disease biology and treatment efficacy and may offer access to novel therapies not otherwise available23.
Examples include studies on high-dose chemotherapy with stem cell rescue and new targeted agents1610. Patients can search for ongoing trials through registries such as those provided by the National Cancer Institute23.
Prognosis and Survival Rates
“People are sometimes hesitant to use the word cure. But we want to know if we can help people control their cancer and live for a long time without being on constant therapy.”
— Heather Parsons, Dana-Farber Cancer Institute17
Metastatic breast cancer remains incurable, but treatment can extend survival and improve symptoms224. Without treatment, median survival is approximately 2.5 months, while with therapy, median survival extends to about three years2.
Survival varies by tumor subtype and patient factors. The five-year survival rate is about 31% overall, but only 12% for triple-negative breast cancer and 19% for metastatic inflammatory breast cancer23. Advances in treatment have improved survival over recent decades25.
| Breast Cancer Subtype | Approximate 5-Year Survival Rate |
|---|---|
| Overall Metastatic Breast Cancer | 31%23 |
| Triple-Negative Breast Cancer | 12%23 |
| Metastatic Inflammatory Breast Cancer | 19%2 |
| Sources:23 | |
Living With Metastatic Breast Cancer
Living with metastatic breast cancer involves ongoing treatment, regular monitoring, and managing physical and emotional challenges23. Patients are encouraged to be advocates for their care by staying informed, asking questions, and engaging with support communities3.
Emotional distress is common, and psychosocial support helps patients cope with fear, uncertainty, and changes in quality of life21. Mindfulness, enjoyable activities, and support from loved ones contribute to emotional resilience21.
